Abstract 1257P
Background
Double heterozygous (DH) is a rare event, in DH patients, two pathogenic variants (PV) in two genes are present in the genomic DNA. Next-generation sequencing technologies with expanded gene, and affordable and more complete tools for diagnosis in hereditary cancer field, resulted in the identification of unexpected variants, including more than one variant in a single patient. The aim of this study was to identify the prevalence of double heterozygous and determine the effect of two pathogenic variants in hereditary cancer syndromes patients from Northeast Mexico.
Methods
This multicentric study included patients from the CECIL (The CUCC Early Cancer Detection Clinic) Hereditary Cancer Registry, and from the Hereditary Cancer Program from Tec Salud. Both centers accomplish patients of the Nuevo León state and adjacent states of Northern Mexico. Patients were recruited in a period of 7 years (from March of 2016 to March of 2023), a total of 872 patients were evaluated by Medical Geneticists and tested with NGS multigene cancer panel tests.
Results
A total of 294 (33.7%) patients had at least one PV, and 9 (3%) DH (two PV). Of all the DH patients, 8 (88.8%) had the clinical diagnosis of HBOC (Hereditary Breast Hereditary Cancer Syndrome), and one (11.1%) had Lynch Syndrome diagnosis. The mean age of cancer diagnosis was 42.8 years, compared with 40.3 mean for all the analyzed patients. None of the DH patients (0%) had synchronic or metachronic neoplasias diagnosed, compared to 19 (6.46%) with one PV patients. Among the identified variants BRCA1/2 and other homologous repair genes were found in 8 (88.8%) patients. The most frequent gene identified was MUTYH in 5 (55.5%) patients, surprisingly the variant c.1187G>A, known as a founder mutation in Northern Europe, was found in 4/5 (80%). These four Mexican patients had not known European ancestry.
Conclusions
This study suggest that the concurrence of two pathogenic variants did not impact the age of diagnosis or the risk of developing multiple neoplasia. variant c.1187G>A MUTYH founder mutation is frequent in our mestizo population and the most frequently found in the double heterozygous state.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Centro Universitario Contra el Cancer Hospital Dr Jose Eleuterio Gonzalez UANL. Centro de Cancer de Mama Hospital Zambrano Hellion Tec Salud.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1203P - Role of tumor markers before or during chemotherapy for poorly differentiated neuroendocrine carcinomas of the digestive system: An exploratory analysis of JCOG1213
Presenter: Tomoyuki Satake
Session: Poster session 14
1204TiP - Iadademstat in combination with paclitaxel in relapsed/refractory small cell lung carcinoma (SCLC) and extrapulmonary high grade neuroendocrine carcinoma (NEC)
Presenter: Neel Belani
Session: Poster session 14
1212P - Predictive value of a near-term prediction model for severe irAEs in cancer treatment with ICIs
Presenter: Jun Zhao
Session: Poster session 14
1213P - HRD complete: A novel NGS assay for detecting homologous recombination repair (HRR) gene alterations in prostate cancer
Presenter: Xin Ye
Session: Poster session 14
1214P - A novel machine learning based method to detect homozygous deletion of homologous recombination repair (HRR) genes in prostate cancer
Presenter: Jianqing Wang
Session: Poster session 14
1215P - Comparative analysis of cfDNA liquid biopsy and tumor-based next-generation sequencing (NGS) approaches
Presenter: Anastasiya Yudina
Session: Poster session 14
1216P - A spectroscopic liquid biopsy for the earlier detection of multiple cancer types
Presenter: Matthew Baker
Session: Poster session 14
1217P - Clinical evaluation of a CE-IVD liquid biopsy pan cancer genomic profiling test
Presenter: Timothy Crook
Session: Poster session 14
1218P - Exploring cancer care pathways in seven European countries: Identifying obstacles and opportunities for the role of artificial intelligence
Presenter: Shereen Nabhani
Session: Poster session 14